NCT04323956 2026-02-02
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
Phase 1 Active not recruiting
Clinical Trials
1 trialsLymphoma, Large B-Cell, Diffuse × pegylated granulocyte colony-stimulating factor × 90 days × Clear all